BridgeBio Pharma Acoramidis Reduces All-Cause Death 44.7% and Cardiovascular Death 49.3% at 54 Months
BridgeBio Pharma presented 54-month open-label data showing acoramidis reduced all-cause mortality by 44.7% and cardiovascular mortality by 49.3% versus placebo (p<0.0001) with sustained tolerability. Attruby is approved by the FDA and BEYONTTRA by the EMA, and further trial data are planned for upcoming medical meetings.
1. Open-Label Extension Findings
BridgeBio Pharma presented 54-month open-label extension data for acoramidis (Attruby/BEYONTTRA), showing a 44.7% reduction in all-cause mortality risk and a 49.3% reduction in cardiovascular mortality risk compared with placebo (p<0.0001).
2. Safety Profile
The trial reported sustained tolerability over 54 months, with no new safety concerns emerging, reinforcing the long-term safety profile of acoramidis in ATTR-CM patients.
3. Regulatory Approvals and Next Steps
Acoramidis is approved in the United States as Attruby and in Europe as BEYONTTRA. BridgeBio Pharma plans to unveil additional long-term data at upcoming medical meetings, potentially expanding its commercial and clinical footprint.